U.S. RESEARCH ROUNDUP-Brighthouse Financial, Microsoft, Shattuck Labs
Brief: Disc Medicine Announces Underwritten Offering Of Common Stock
Brief: Disc Medicine Inc - Announced Positive Additional Data For Bitopertin
Disc Medicine Inc reports results for the quarter ended in March - Earnings Summary
U.S. RESEARCH ROUNDUP- Biomea Fusion, BlackRock, Capital Bancorp
U.S. STOCKS ON THE MOVE-Eiger BioPharmaceuticals, Reddit, US energy sector
U.S. STOCKS ON THE MOVE-Trump Media & Technology, Semtech, General Dynamics
U.S. STOCKS ON THE MOVE-Guess, Crypto stocks, Liquidia
Disc Medicine falls as genetic disorder drug fails to meet key secondary goal in mid-stage study
Brief: Disc Reports Topline Results From Phase 2 AURORA Study Of Bitopertin In Patients With Erythropoietic Protoporphyria
Brief: Disc Reports Topline Results From Phase 2 Aurora Study Of Bitopertin In Patients With Erythropoietic Protoporphyria (EPP)
Brief: Disc Medicine Appoints Pamela Stephenson As Chief Commercial Officer
Brief: Disc Medicine Announces Retirement Of Brian Macdonald, As Chief Innovation Officer
Brief: Disc Says Updated Results From Phase 2 Beacon Study Of Bitopertin
Brief: Disc Presents Initial Positive Data From Ongoing Phase 1B/2 Trial Of Disc-0974 In Patients With Myelofibrosis (MF) And Anemia
Brief: Disc Medicine Jefferies Entered Into Amendment To An Open Market Sale Agreement
Brief: Disc Medicine Inc Files For Mixed Shelf Of Up To $400 Mln
Brief: Disc Medicine Q3 basic EPS USD -0.58
Brief: Disc Medicine Inc Topline Aurora Data Is Expected To Be Presented In Early 2024